18.01.2013 - British vaccine specialist PsiOxus Therapeutics Ltd. has baged a US$3.3m development contract from US Defense Threat Reduction Agency.
Under the terms of the agreement, the Oxford-based company will develop biodefence vaccine adjuvants. Using its PolyMAP platform, the company’s research will be aimed at improving safety and efficacy of two existing vaccine candidates: the recombinant protective antigen (rPA) against Anthrax and the Venezuelan Equine Encephalopathy Virus (VEEV). A monoclonal antibody targeting Anthrax has been recently approved by the US FDA.
The contract will support work over a three-year period in the US, as well as in the company’s new laboratory in Oxford, which has been designed and equipped as a category two laboratory for the handling of live viruses.
PsiOxus Therapeutics’ PolyMAP technology links polymers to synthetic adjuvants that activate specific sets of Toll-like receptors (TRLs), which significantly boosts the effectiveness of vaccines in a controlled manner.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.